A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

Investigational New Drugs

Volumn 15, Issue 4, 1997, Pages 331-341

  Brand, Randall ^a,b   Capadano, Mary ^a   Tempero, Margaret ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Gemcitabine; Pancreatic cancer; Phase I; Prolonged infusion

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; GEMCITABINE; HEMOGLOBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ASCITES; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; LIVER CELL CARCINOMA; MALE; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPHIL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTOPENIA; TIME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD CELL COUNT; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031406423     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005981317532     Document Type: Article

References (20)

1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Rindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-Difluoro-2′-deoxycytidine). Cancer Res 40:4417-4422, 1990
2. Grindey GB: Current status of cancer drug development: Failure or limited success? Cancer Cells 2:163-171, 1990
3. Anderson H, Lund B, Back F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
4. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg T: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
5. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
6. Pollera CF, Ceribelli A, Crecco M, Calabreso F: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994
7. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Nat Cancer Inst 86:1530-1533, 1994
8. Catimel G, Vermorken JB, Clavel M, Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:543-647, 1994
9. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
10. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995
11. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
12. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
13. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
14. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced or metastatic solid tumors. Invest New Drugs 12:111-119, 1994
15. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG, VonHoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days [letter]. Eur J Cancer 30A:417-418, 1994
16. Poplin EAD, Corbett T, Flaherty L, Tarassoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs 10:165-170, 1992
17. Clavel M, Guastella J, Peters G: Phase I study of LY-188011, 2′,2′-difluorodeoxycytidine. Invest New Drugs 7:379, 1989
18. Fossella FV, Lippman SM, Tarassoff P, Shin DM, Calayag M, Lee JS, Murphy WK, Perez-Soler R, Glisson BS, Hong WK: Phase I/II study of gemcitabine: An active agent for non-small cell lung cancer (NSCLC). Proc ASCO 14:371, 1995 (abstr 1144)
19. Tonato M, Mosconi AM, Martin C: Safety profile of gemcitabine. Anti-Cancer Drugs 6:27-32, 1995
20. Moore M, Andersen J, Burrls H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, VonHoff D: A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 14:199, 1995 (abstr 473)